3,121 Shares in The Clorox Company (NYSE:CLX) Acquired by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP bought a new stake in The Clorox Company (NYSE:CLX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,121 shares of the company's stock, valued at approximately $460,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Clorox during the fourth quarter worth $259,041,000. FMR LLC grew its stake in shares of Clorox by 75.4% in the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after buying an additional 585,526 shares in the last quarter. KBC Group NV grew its stake in shares of Clorox by 688.7% in the first quarter. KBC Group NV now owns 587,679 shares of the company's stock valued at $86,535,000 after buying an additional 513,171 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Clorox by 549.8% in the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock valued at $88,144,000 after buying an additional 459,203 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its stake in shares of Clorox by 187.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after buying an additional 456,114 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Stock Up 0.2%

Shares of NYSE CLX traded up $0.20 during midday trading on Thursday, reaching $131.63. 1,508,363 shares of the company's stock were exchanged, compared to its average volume of 1,792,713. The Clorox Company has a 52-week low of $117.35 and a 52-week high of $171.37. The stock has a market capitalization of $16.22 billion, a PE ratio of 23.63, a price-to-earnings-growth ratio of 3.46 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The business's fifty day moving average price is $126.88 and its two-hundred day moving average price is $140.49.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the previous year, the firm earned $1.71 earnings per share. The business's revenue was down 8.0% on a year-over-year basis. Analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Analysts Set New Price Targets

CLX has been the subject of a number of research reports. Jefferies Financial Group dropped their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Barclays set a $119.00 target price on Clorox and gave the stock an "underweight" rating in a research note on Tuesday, July 15th. UBS Group lowered their target price on Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Citigroup reaffirmed a "neutral" rating and set a $135.00 price target (down from $140.00) on shares of Clorox in a report on Tuesday, July 15th. Finally, Wells Fargo & Company decreased their price target on Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a report on Wednesday, July 9th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, Clorox currently has an average rating of "Hold" and an average price target of $145.17.

Insider Buying and Selling

In related news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director directly owned 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.57% of the stock is currently owned by insiders.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.